News
The combination of Bayer's mineralocorticoid receptor antagonist (MRA) finerenone and Boehringer Ingelheim and Eli Lilly's ...
In another sign of recovery in digital health investing, Omada Health has priced an initial public offering (IPO) of $19 per ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback